Impact des critères de jugement sur l’optimisation de la détermination du nombre de sujet nécessaires pour qualifier un bénéfice clinique dans des essais cliniques en cancérologie

Abstract : In oncology clinical trial, overall survival (OS) benefit is the gold standard for the approval of new anticancer by the regulatory agencies as the FDA. The need to reduce long-term follow-up, sample size and cost of clinical trials led to use some intermediate endpoint for OS to assess earlier efficacy of treatments. The intermediate endpoints are often used as primary endpoints because they can be assessed earlier and most of the time, these endpoints are composite endpoints because they combine different events. Nevertheless, composite endpoints suffer from important limitations specially the variability of their definitions, which is recognized as a major methodological problem. In this context, the DATECAN-1 project has been developed to provide recommendations and to standardize definitions of time-to-event composite endpoints for each specific diseases and at each specific stage by use of a formal consensus methodology. To validate surrogate endpoints, Buyse and colleagues developed a method based on individual-data meta-analysis, which assesses “individual-level” surrogacy and “trial-level” surrogacy, which is considered as the gold standard.Phase III cancer clinical trials investigators employ more and more two co-primary endpoints. However, an important challenge, in the conception of clinical trials is the sample size calculation according to the main objective(s) and the ability to manage multiple co-primary endpoints. The determination of sample size is fundamental and critical elements in the design of phase III clinical trial. If the sample size is too small, important effects may be go unnoticed. If it is too large, it represents a waste of resources and unethically puts more participants at risk than necessary. The statistical power depends on the total number of events rather than on total sample size.The objectives of my thesis project are:1) To study the impact of the definitions of time-to-event endpoint from the DATECAN-1 consensus on the results and conclusions of the trials published in pancreatic cancer.2) To study the properties of the potential surrogate to the overall survival.3) To propose a design for the determination of sample size necessary for a phase III clinical study with co-primary time-to-event such as progression-free survival and time to quality of life deterioration.The final objective of my thesis project is to develop an R package for the calculation of the number of subjects needed with the co-primary time-to-event in phase III clinical trials.
Complete list of metadatas

Cited literature [69 references]  Display  Hide  Download

https://tel.archives-ouvertes.fr/tel-02145999
Contributor : Abes Star <>
Submitted on : Monday, June 3, 2019 - 3:14:59 PM
Last modification on : Tuesday, June 11, 2019 - 12:20:27 PM

File

these_A_PAM_Alhousseiny_2017.p...
Version validated by the jury (STAR)

Identifiers

  • HAL Id : tel-02145999, version 1

Collections

Citation

Alhousseiny Pam. Impact des critères de jugement sur l’optimisation de la détermination du nombre de sujet nécessaires pour qualifier un bénéfice clinique dans des essais cliniques en cancérologie. Cancer. Université Bourgogne Franche-Comté, 2017. Français. ⟨NNT : 2017UBFCE024⟩. ⟨tel-02145999⟩

Share

Metrics

Record views

135

Files downloads

23